Serum Amyloid A as a Surrogate Marker for Mucosal and Histologic Inflammation in Patients with Crohn’s Disease.

Serum Amyloid A as a Surrogate Marker for Mucosal and Histologic Inflammation in Patients with Crohn’s Disease. Inflamm Bowel Dis. 2016 Dec 07; Authors: Yarur AJ, Quintero MA, Jain A, Czul F, Barkin JS, Abreu MT Abstract BACKGROUND: Serum amyloid A (SAA) is an acute-phase protein, but its role as a biomarker of disease activity in Crohn’s disease is unclear. The aim of the study was to assess the correlation between SAA, inflammatory cytokines, and mucosal inflammation in patients with Crohn’s disease and to investigate whether this marker might be…

Read More

Ongoing Symptoms in Ulcerative Colitis Patients in Remission: Irritable Bowel Syndrome or Gastrointestinal Symptoms in the Absence of Inflammation?

Ongoing Symptoms in Ulcerative Colitis Patients in Remission: Irritable Bowel Syndrome or Gastrointestinal Symptoms in the Absence of Inflammation? Inflamm Bowel Dis. 2016 Dec 07; Authors: Gracie DJ, Ford AC PMID: 27930410 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/27930410?dopt=Abstract

Read More

Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.

Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. Inflamm Bowel Dis. 2016 Dec 07; Authors: Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K Abstract BACKGROUND: Vedolizumab is a gut-selective α4β7 integrin antagonist for the treatment of moderately to severely active Crohn’s disease (CD). Aims of this study were to characterize the efficacy and safety of vedolizumab induction and maintenance therapy in patients who were naïve to tumor…

Read More

Zinc Deficiency is Associated with Poor Clinical Outcomes in Patients with Inflammatory Bowel Disease.

Zinc Deficiency is Associated with Poor Clinical Outcomes in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Dec 07; Authors: Siva S, Rubin DT, Gulotta G, Wroblewski K, Pekow J Abstract BACKGROUND: Zinc plays a pivotal role in wound repair, tissue regeneration, and the immune response. Although zinc deficiency is common in patients with inflammatory bowel disease (IBD), the impact of low serum zinc levels on disease course is not known. METHODS: Patients enrolled in a prospectively collected IBD registry with at least 2 serum zinc measurements were included…

Read More

Comprehensive DNA Methylation Profiling of Inflammatory Mucosa in Ulcerative Colitis.

Comprehensive DNA Methylation Profiling of Inflammatory Mucosa in Ulcerative Colitis. Inflamm Bowel Dis. 2016 Dec 07; Authors: Tahara T, Hirata I, Nakano N, Nagasaka M, Nakagawa Y, Shibata T, Ohmiya N Abstract INTRODUCTION: Aberrant DNA methylation frequently occurs in the inflammatory mucosa in ulcerative colitis (UC) and is involved in UC-related tumorigenesis. We performed comprehensive DNA methylation profiling of the promoter regions of the inflamed rectal mucosae of patients with UC. DESIGN: The methylation status of the promoter CpG islands (CGIs) of 45 cancer/inflammation or age-related candidate genes and the…

Read More

Systematic review with meta-analysis: recurrence of Crohn’s disease after total colectomy with permanent ileostomy.

Related Articles Systematic review with meta-analysis: recurrence of Crohn’s disease after total colectomy with permanent ileostomy. Aliment Pharmacol Ther. 2016 Dec 08;: Authors: Fumery M, Dulai PS, Meirick P, Farrell AM, Ramamoorthy S, Sandborn WJ, Singh S Abstract BACKGROUND: Subtotal or total colectomy or proctocolectomy with permanent ileostomy (TC-PI) may be a treatment option for medically refractory colonic Crohn’s disease (CD). AIM: To perform a systematic review and meta-analysis to evaluate the rate, risk factors and outcomes of CD recurrence after TC-PI. METHODS: In a systematic review ending 31 March…

Read More

Restorative Proctocolectomy in Elderly IBD Patients: A Multicentre Comparative Study on Safety and Efficacy.

Related Articles Restorative Proctocolectomy in Elderly IBD Patients: A Multicentre Comparative Study on Safety and Efficacy. J Crohns Colitis. 2016 Dec 07;: Authors: Colombo F, Sahami S, de Buck Van Overstraeten A, Tulchinsky H, Mege D, Dotan I, Foschi D, Leo CA, Warusavitarne J, D’Hoore A, Panis Y, Bemelman W, Sampietro GM Abstract BACKGROUND AND AIMS: Restorative proctocolectomy in elderly inflammatory bowel disease [ IBD] patients is controversial and limited data are available on the outcomes of surgery. The aim of this study was to evaluate the safety, efficacy, and…

Read More

ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.

Related Articles ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update. J Crohns Colitis. 2016 Dec 07;: Authors: Danese S, Fiorino G, Raine T, Ferrante M, Kemp K, Kierkus J, Lakatos PL, Mantzaris G, van der Woude J, Panes J, Peyrin-Biroulet L PMID: 27927718 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/27927718?dopt=Abstract

Read More

Stress Response Protein RBM3 Promotes the Development of Colitis-associated Cancer.

Stress Response Protein RBM3 Promotes the Development of Colitis-associated Cancer. Inflamm Bowel Dis. 2016 Dec 07; Authors: Sakurai T, Kashida H, Komeda Y, Nagai T, Hagiwara S, Watanabe T, Kitano M, Nishida N, Fujita J, Kudo M Abstract BACKGROUND: Colitis-associated cancer (CAC) is caused by chronic intestinal inflammation and often results from refractory inflammatory bowel disease (IBD). Stress response proteins Cirp and HSPA4 are involved in the refractory clinical course and development of CAC. RNA-binding motif protein 3 (RBM3) is induced in response to various stresses and is upregulated in…

Read More

The Cost of Crohn’s Disease: Varied Health Care Expenditure Patterns Across Distinct Disease Trajectories.

The Cost of Crohn’s Disease: Varied Health Care Expenditure Patterns Across Distinct Disease Trajectories. Inflamm Bowel Dis. 2016 Dec 07; Authors: Rao BB, Click BH, Koutroubakis IE, Ramos Rivers C, Regueiro M, Swoger J, Schwartz M, Hashash J, Barrie A, Dunn MA, Binion DG Abstract BACKGROUND: Patients with Crohn’s disease (CD) encompass a heterogeneous disease spectrum, with variable health care utilization and expenditure patterns. Lémann Index (LI) is a metric that quantifies cumulative bowel damage and has shown utility in delineating distinct disease phenotypes. We aimed to characterize the financial…

Read More